Cargando...
Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer
Durvalumab after concurrent chemoradiation has significantly improved survival in stage III non-small cell lung cancer (NSCLC). However, there is limited data evaluating the utilization and challenges to deliver durvalumab consolidation in the real world. We assessed the use of consolidative durvalu...
Guardado en:
| Publicado en: | Radiother Oncol |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7523024/ https://ncbi.nlm.nih.gov/pubmed/31786421 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.radonc.2019.11.015 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|